Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1975 2
1976 1
1980 2
1981 2
1982 2
1983 4
1984 5
1985 6
1986 7
1987 9
1988 6
1989 9
1990 12
1991 18
1992 19
1993 30
1994 29
1995 24
1996 20
1997 31
1998 21
1999 19
2000 42
2001 27
2002 36
2003 47
2004 39
2005 45
2006 40
2007 65
2008 55
2009 62
2010 60
2011 72
2012 90
2013 101
2014 96
2015 77
2016 68
2017 74
2018 92
2019 84
2020 91
2021 85
2022 87
2023 80
2024 40

Text availability

Article attribute

Article type

Publication date

Search Results

1,669 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Bladder Urothelial Carcinoma, High Grade"
Page 1
Management of High-grade T1 Urothelial Carcinoma.
Reisz PA, Laviana AA, Chang SS. Reisz PA, et al. Curr Urol Rep. 2018 Oct 26;19(12):103. doi: 10.1007/s11934-018-0850-8. Curr Urol Rep. 2018. PMID: 30367268 Review.
PURPOSE OF REVIEW: The optimal management of high-grade T1 (HGT1) urothelial carcinoma (UC) is complex given its high rate of recurrence, progression, and cancer-specific mortality as well as its clinical variability. ...The integration of new i …
PURPOSE OF REVIEW: The optimal management of high-grade T1 (HGT1) urothelial carcinoma (UC) is complex given its …
International Society of Urological Pathology (ISUP) Consensus Conference on Current Issues in Bladder Cancer. Working Group 2: Grading of Mixed Grade, Invasive Urothelial Carcinoma Including Histologic Subtypes and Divergent Differentiations, and Non-Urothelial Carcinomas.
Paner GP, Kamat A, Netto GJ, Samaratunga H, Varma M, Bubendorf L, van der Kwast TH, Cheng L; Members of the ISUP Bladder Tumor Consensus Panel. Paner GP, et al. Am J Surg Pathol. 2024 Jan 1;48(1):e11-e23. doi: 10.1097/PAS.0000000000002077. Epub 2023 Jun 29. Am J Surg Pathol. 2024. PMID: 37382156
The 2022 International Society of Urological Pathology (ISUP) Consensus Conference on Urinary Bladder Cancer Working Group 2 was tasked to provide evidence-based proposals on the applications of grading in noninvasive urothelial carcinoma with m …
The 2022 International Society of Urological Pathology (ISUP) Consensus Conference on Urinary Bladder Cancer Working Group 2 w …
Pediatric urothelial bladder neoplasm.
Galiya R, Stanislav K, Jawdat J, Benjamin H, Boris C. Galiya R, et al. J Pediatr Urol. 2022 Dec;18(6):833.e1-833.e4. doi: 10.1016/j.jpurol.2022.06.026. Epub 2022 Jun 30. J Pediatr Urol. 2022. PMID: 35871900
OBJECTIVES: To report our experience and long-term follow-up data on pediatric patients with urothelial carcinoma of the urinary bladder. METHODS: In this retrospective two center study, we analyzed the perioperative and long-term follow-up data of nin …
OBJECTIVES: To report our experience and long-term follow-up data on pediatric patients with urothelial carcinoma of the ur …
Mutational landscape of non-muscle-invasive bladder cancer.
Hurst CD, Knowles MA. Hurst CD, et al. Urol Oncol. 2022 Jul;40(7):295-303. doi: 10.1016/j.urolonc.2018.10.015. Epub 2018 Nov 13. Urol Oncol. 2022. PMID: 30446444 Free article. Review.
Grading of Ta tumors subdivides these lesions into papillary urothelial neoplasms of low malignant potential and low- and high-grade noninvasive papillary urothelial carcinoma. CIS is by definition high-grade and the majorit …
Grading of Ta tumors subdivides these lesions into papillary urothelial neoplasms of low malignant potential and low- and h …
High-grade Ta urothelial carcinoma and carcinoma in situ of the bladder.
Sylvester RJ, van der Meijden A, Witjes JA, Jakse G, Nonomura N, Cheng C, Torres A, Watson R, Kurth KH. Sylvester RJ, et al. Urology. 2005 Dec;66(6 Suppl 1):90-107. doi: 10.1016/j.urology.2005.06.135. Urology. 2005. PMID: 16399418 Review.
The English-language literature on high-grade Ta urothelial carcinoma and CIS was identified and critically reviewed by a panel of 9 international experts. ...High-grade Ta urothelial carcinoma and CIS are relatively rare tu …
The English-language literature on high-grade Ta urothelial carcinoma and CIS was identified and critically revi …
pT1 high-grade bladder cancer: histologic criteria, pitfalls in the assessment of invasion, and substaging.
Raspollini MR, Montironi R, Mazzucchelli R, Cimadamore A, Cheng L, Lopez-Beltran A. Raspollini MR, et al. Virchows Arch. 2020 Jul;477(1):3-16. doi: 10.1007/s00428-020-02808-6. Epub 2020 Apr 15. Virchows Arch. 2020. PMID: 32296929 Review.
Most patients with bladder carcinoma are diagnosed with non-muscle-invasive disease, stage Ta, and pT1. Stage remains as the single most important prognostic indicator in urothelial carcinoma. Among the pT1 bladder cancer patients, recurr …
Most patients with bladder carcinoma are diagnosed with non-muscle-invasive disease, stage Ta, and pT1. Stage remains as the s …
Urothelial Carcinoma In Situ (CIS): New Insights.
Akhtar M, Al-Bozom IA, Ben Gashir M, Taha NM, Rashid S, Al-Nabet ADMH. Akhtar M, et al. Adv Anat Pathol. 2019 Sep;26(5):313-319. doi: 10.1097/PAP.0000000000000239. Adv Anat Pathol. 2019. PMID: 31149909 Review.
Urothelial carcinoma in situ (CIS) is a high-grade noninvasive malignancy with a high tendency of progression. ...Urothelial CIS may be categorized as primary when it is not associated with any past or present urothelial carcino …
Urothelial carcinoma in situ (CIS) is a high-grade noninvasive malignancy with a high tendency of progres …
T1 bladder carcinoma with variant histology: pathological features and clinical significance.
Lopez-Beltran A, Blanca A, Cimadamore A, Montironi R, Luque RJ, Volavšek M, Cheng L. Lopez-Beltran A, et al. Virchows Arch. 2022 May;480(5):989-998. doi: 10.1007/s00428-021-03264-6. Epub 2022 Feb 4. Virchows Arch. 2022. PMID: 35122124 Free PMC article.
The aim of the study was to stratify high-grade T1 (HGT1) bladder urothelial carcinoma into risk categories based on the presence of variant histology when compared to conventional urothelial carcinoma. The clinicopathological feat …
The aim of the study was to stratify high-grade T1 (HGT1) bladder urothelial carcinoma into risk categori …
Stratification of urothelial bladder carcinoma depending on immunohistochemical expression of GATA3 and CK5/6.
Serag Eldien MM, Abdou AG, Elghrabawy GRA, Alhanafy AM, Mahmoud SF. Serag Eldien MM, et al. J Immunoassay Immunochem. 2021 Nov 2;42(6):662-678. doi: 10.1080/15321819.2021.1937212. Epub 2021 Jun 9. J Immunoassay Immunochem. 2021. PMID: 34106817
Bladder urothelial carcinoma (BUC) has two pathways with distinct molecular features and prognosis, non-muscle invasive (NMI) and muscle invasive (MI) tumors. ...Pure urothelial carcinoma and NMI were in favor of luminal group (GATA3 +ve/ …
Bladder urothelial carcinoma (BUC) has two pathways with distinct molecular features and prognosis, non-muscle i …
The Emerging Molecular Landscape of Urothelial Carcinoma.
Solomon JP, Hansel DE. Solomon JP, et al. Surg Pathol Clin. 2016 Sep;9(3):391-404. doi: 10.1016/j.path.2016.04.004. Surg Pathol Clin. 2016. PMID: 27523968 Review.
Historically, a two-pathway model had been applied to distinguish low- and high-grade urothelial carcinoma, although significant overlap and increasing complexity of molecular alterations has been recently described. In many cases, mutations in HRAS an …
Historically, a two-pathway model had been applied to distinguish low- and high-grade urothelial carcinoma, alth …
1,669 results